Jacosa, being out of country and just on an IPad, I missed this from earlier today! Salveen Richter raised INCY price target from $65 to $ 79. Interesting that now these guys have the highest PT on the street, and they have only assigned a $1.5 Billion for all other drugs in the pipeline besides RUXO. I am sure you know more about this,I since you probably have a feed of some of these street analyst reports. I was surprised by the DCF/NPV analysis leading to this PT, because the peak sales assumption for Ruxo in 2019 was assumed to be a bit less than $375 Million. Any info or thoughts?
So sorry, in previous post it should read peak sales for RUXO in PV of just under $375 Million in 2019...,
So, that's like another 25% from here! And INCY is now in their top sector pick! I find it bizarre that most of these guys, except Wei of Jefferies had their targets, earlier this year, in the mid to upper $20's.